Eloxx Pharmaceuticals announces publication of Phase 2a exaluren data in Alport syndrome
ELOX•Eloxx Pharmaceuticals announced publication of Phase 2a data for exaluren in nonsense mutation Alport syndrome in the Journal of Clinical Investigation.
ELOX•Eloxx Pharmaceuticals announced publication of Phase 2a data for exaluren in nonsense mutation Alport syndrome in the Journal of Clinical Investigation.
Eloxx Pharmaceuticals announced that Phase 2a exaluren data in nonsense mutation Alport syndrome were published in the Journal of Clinical Investigation.